No Data
No Data
Form 144 | Cisco(CSCO.US) Insider Proposes to Sell 4.82 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 25, $Cisco(CSCO.US)$ Insider JEFFERY SHARRITTS intends to sell 100.89K shares of its common stock on Jul 25, with a total market value of approximately $4.82 million.
Performance Comparison: Cisco Systems And Competitors In Communications Equipment Industry
Empowering Growth: My Journey With the Cisco MentorMe Program
Tech Sell-off to Be Short Lived; This Is Start of Tech Bull Run: Wedbush
Haisco Pharmaceutical Group (002653.SZ) has gained approval to conduct clinical trials on the innovative drug HSK39004 inhalation suspension.
On July 25th, Geelong News reported that Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Tibet Haisco Pharmaceutical Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. After review, the HSK39004 inhalation suspension, which was accepted in May 2024, meets the requirements for drug registration, and the clinical trial of the drug is approved. HSK39004 is a new targeted small molecule inhibitor with independent intellectual property rights independently developed by the company. It is clinically intended for the treatment of chronic obstructive pulmonary Disease. The preclinical research results show that HSK39004 has a good therapeutic effect on COPD in vitro.
AI dreams, Silicon Valley persists, while Wall Street hesitates.
"Follow the money" on Wall Street believes that AI technology has not yet reached the expected level of practicality, investing too much not only fails to recover costs, but also easily triggers a bubble. However, technology giants in the midst of the AI whirlpool are still frantically investing money, aiming for a future.